BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Krishnan A, Patel RA, Hadi YB, Mukherjee D, Shabih S, Thakkar S, Singh S, Woreta TA, Alqahtani SA. Clinical characteristics and outcomes of COVID-19 in patients with autoimmune hepatitis: A population-based matched cohort study. World J Hepatol 2023; 15(1): 68-78 [PMID: 36744163 DOI: 10.4254/wjh.v15.i1.68]
URL: https://www.wjgnet.com/2307-8960/full/v15/i1/68.htm
Number Citing Articles
1
Shiuan‐Tzuen Su, Chun‐Yu Lin, Renin Chang. Effect of SARS‐CoV‐2 Infection Increased the Risk of Autoimmune DisorderInternational Journal of Rheumatic Diseases 2025; 28(6) doi: 10.1111/1756-185X.70279
2
Wan-Hsuan Hsu, Bo-Wen Shiau, Ting-Hui Liu, Jheng-Yan Wu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai, Chi-Hsing Chen. Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosisExpert Review of Anti-infective Therapy 2023; 21(10): 1143 doi: 10.1080/14787210.2023.2267846
3
Arunkumar Krishnan, Carolin V. Schneider, Yousaf Hadi, Diptasree Mukherjee, Bandar AlShehri, Saleh A. Alqahtani. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort studyDiabetologia 2024; 67(3): 483 doi: 10.1007/s00125-023-06057-5
4
Shih-Chieh Shao, Daniel Hsiang-Te Tsai, Albert Tzu-Ming Chuang, Kuan-Hung Liu, Edward Chia-Cheng Lai, Ronald C. W. Ma. SGLT2 inhibitors, GLP-1 RAs, and DPP4 inhibitors and the risk of hypomagnesemia in type 2 diabetes: A target trial emulationPLOS Medicine 2026; 23(3): e1004968 doi: 10.1371/journal.pmed.1004968